Scholarly Index
Arnold von Eckardstein
University Hospital of Zurich; 36,318 total citations; 703 total publications; best world rank #31
University Hospital of Zurich
36,318Total citations
703Total publications
101H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Cancer, Lipids, and Metabolism | Lifetime | 76 | CH 3 | 99.59 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 68 | CH 1 | 99.65 |
| Cholesterol and Lipid Metabolism | Lifetime | 31 | CH 2 | 99.40 |
| Lipoproteins and Cardiovascular Health | Lifetime | 84 | CH 2 | 99.53 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 144 | CH 5 | 98.69 |
| Lipid metabolism and disorders | Lifetime | 106 | CH 2 | 98.53 |
| Drug Transport and Resistance Mechanisms | Lifetime | 429 | CH 12 | 98.08 |
| Sphingolipid Metabolism and Signaling | Lifetime | 110 | CH 3 | 97.75 |
| Hormonal and reproductive studies | Lifetime | 575 | CH 4 | 97.32 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 47 | CH 1 | 96.20 |
| Caveolin-1 and cellular processes | Lifetime | 500 | CH 8 | 88.79 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 99 | CH 2 | 97.54 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 149 | CH 2 | 95.56 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 853 | CH 2 | 84.92 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 137 | CH 6 | 84.60 |